Does HAP Cover Zepbound in Michigan? Commercial, Medicaid, and Medicare

Whether Health Alliance Plan covers Zepbound depends on which HAP plan you have and why the drug was prescribed. Most HAP commercial plans exclude Zepbound when it is prescribed for weight loss. Coverage becomes possible when the prescription is for obstructive sleep apnea, when a HAP CareSource Medicaid member meets Michigan’s tightened morbid obesity criteria, or when a Medicare Advantage member qualifies for the federal GLP-1 Bridge program that begins July 1, 2026.

Commercial Plans Generally Exclude Zepbound for Weight Loss

For HAP’s individual, family, and employer-sponsored coverage, weight loss medications are broadly excluded. HAP’s own weight management page states that prescription weight loss drugs are covered only on a “limited basis” when a doctor determines medical necessity and the plan includes prescription drug coverage.¹ In practice, many commercial HAP contracts list Zepbound by name as an excluded drug.

A May 2025 ruling from the Michigan Department of Insurance and Financial Services shows how firmly this exclusion holds. In DIFS Case 235117, a parent sought reimbursement for Zepbound prescribed to a minor with autism spectrum disorder, insulin resistance, and morbid obesity. HAP’s contract stated that “drugs used for weight loss, other than those designated as covered for weight loss on our formulary, are listed as an excluded service,” and Zepbound appeared on the exclusion list. The petitioner argued the drug should be covered as a habilitative treatment for autism-related overeating. An independent review organization found Zepbound is not an evidence-based autism treatment and that the prescription was effectively for morbid obesity. The DIFS director upheld HAP’s denial.²

Coverage for Obstructive Sleep Apnea

Zepbound has a second FDA-approved use: moderate to severe obstructive sleep apnea in adults with obesity. HAP’s medical policy allows approval for this indication even on plans that exclude the drug for weight loss. The policy states plainly that “Zepbound will not be covered for weight loss” but will be considered for OSA when clinical criteria are met.³

To qualify, a member generally needs:

A sleep study confirming moderate to severe OSA, with an apnea-hypopnea index of 15 or more events per hour.
A BMI of 30 or higher.
Consistent CPAP use, or documentation that CPAP cannot be tolerated because of anatomic issues or severe anxiety.
A prescription from, or consultation with, a neurologist or sleep medicine practitioner.
Concurrent diet and exercise modification.

Requests are denied when the prescription is solely for weight loss, when the patient has type 1 or type 2 diabetes, or when the sleep apnea is central or mixed rather than obstructive. Initial authorization lasts 12 months, with renewal contingent on documented clinical benefit.³

HAP CareSource Medicaid: Tightened Rules as of 2026

Michigan Medicaid members enrolled in HAP CareSource face a different set of rules that changed on January 1, 2026. The state’s bipartisan fiscal year 2026 budget cut pharmaceutical appropriations for GLP-1 obesity drugs by $240 million, and Medicaid tightened its criteria accordingly.⁴

Zepbound stays on the HAP CareSource Medicaid formulary as a non-preferred anti-obesity agent, but weight loss coverage now requires all of the following:⁵⁶

A BMI of 40 or greater (morbid obesity classification).
Documented failure of other clinically appropriate weight loss treatments, including preferred anti-obesity agents such as phentermine and Qsymia.
Evidence that the medication is needed to avoid higher-cost bariatric surgery.

Medicaid coverage for Zepbound continues on the OSA pathway without these obesity-specific restrictions.⁷ Members whose prior authorizations were approved before January 1, 2026, can continue receiving the drug for the remainder of their six-month authorization period.⁸

HAP Medicare Advantage and the GLP-1 Bridge

HAP Medicare Advantage plans have not historically covered Zepbound for weight loss through their Part D formularies. Starting July 1, 2026, a federal option opens up. The Medicare GLP-1 Bridge program, which runs through December 31, 2026, lets eligible Part D enrollees get the Zepbound KwikPen for a flat $50 per month.⁹¹⁰

The program does not require HAP to opt in. Humana runs it centrally under a CMS contract, and providers submit prior authorization requests directly to that processor. To qualify, a member must:

Be enrolled in a Medicare Advantage plan that includes Part D drug coverage.
Not already be receiving a GLP-1 drug through the plan.
Not have type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease.
Meet BMI thresholds: 35 or above, 30 or above with certain cardiovascular or kidney conditions, or 27 or above with other specified diagnoses.

Two caveats. The $50 copay does not count toward the Part D deductible or the annual out-of-pocket cap.¹¹ And only the KwikPen formulation qualifies; single-dose pens and vials do not.¹⁰

Zepbound Is Not Mounjaro

Zepbound and Mounjaro contain the same active ingredient, tirzepatide, but they are separate FDA-approved brands. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management and obstructive sleep apnea. Insurers process claims based on the specific brand and diagnosis code, so the identical molecule can be covered or denied depending on how it is prescribed.¹² Substituting one for the other to reach a different benefit is not a legitimate workaround and typically results in denial.

If HAP Denies Coverage

Medicare Advantage members have 60 calendar days from the written denial notice to file an appeal. Standard appeals are decided within seven calendar days, and expedited appeals, used when a delay could seriously harm the member’s health, are decided within 72 hours. Appeals go to HAP’s Appeal and Grievance Department at 1414 E Maple Rd, Troy, MI 48083, or by fax to (313) 664-5866.¹³ For other plan types, providers initiate prior authorization by faxing the Michigan Prior Authorization Request Form for Prescription Drugs to (313) 664-8045.¹⁴

Michigan residents who believe a denial was improper can also file a complaint with the Department of Insurance and Financial Services, which has ruled on multiple GLP-1 coverage disputes and can order an independent external review.

If coverage stays denied, Eli Lilly’s Zepbound Savings Card can reduce out-of-pocket costs for commercial plan members. Those with commercial insurance that does not cover Zepbound may be eligible for up to $469 off a one-month prescription, capped at seven fills per calendar year. The card is not available to anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits. A separate self-pay savings program starts at $299 for the lowest dose. Both programs expire December 31, 2026, and Lilly can change terms without notice.¹⁵

1
HAP. Weight Management
2
Michigan DIFS. DIFS Case 235117-001, Alliance Health and Life Insurance Company
3
Health Alliance Medical Plans. Policy 3367P
4
Michigan Public. Michigan Cuts Off Weight Loss Drugs for Most Medicaid Patients, Saving $240 Million
5
CareSource. HAP CareSource GLP-1 Changes Network Notification
6
CareSource. Summary of Drug List Changes Effective January 1, 2026
7
University of Michigan Medical Research. Expert Q&A: Michigan Medicaid’s New Limits on GLP-1 Weight Management Medications
8
Michigan MDHHS. Numbered Letter L-25-73, Pharmacy
9
CMS. Medicare GLP-1 Bridge
10
Medicare.gov. Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month
11
Michigan Public. A New Medicare Option for Weight Loss Drugs Is Coming: Here’s What to Know
12
UCHealth. Zepbound Weight Loss Drug Compared to Mounjaro, Wegovy, Ozempic
13
HAP. Appeals
14
HAP. Medication Request Forms for Prior Authorization
15
Eli Lilly. Zepbound Savings